Prognostic factors for survival of patients treated systemically for disseminated melanoma

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1103-1111

  Eton, Omar ^a   Legha, Sewa S ^a   Moon, Thomas E ^a   Buzaid, Antonio C ^a   Papadopoulos, Nicholas E ^a   Plager, Carl ^a   Burgess, Andrew M ^a   Bedikian, Agop Y ^a   Ring, Sigrid ^a   Dong, Qiong ^a   Glassman, Armand B ^a   Balch, Charles M ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA2A INTERFERON; AMSACRINE; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; HYDROXYUREA; LACTATE DEHYDROGENASE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOFT TISSUE CANCER; SURVIVAL TIME;

EID: 0031911497     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1103     Document Type: Article

References (19)

1. Parker SL, Tong T, Bolden S, et al: Cancer statistics 1996. CA Cancer J Clin 46:5-28, 1996
2. Ahmann DL, Creagan, ET, Hahn RG, et al: Complete responses and long-term survivals after systemic chemotherapy for patients with advanced malignant melanoma. Cancer 63:224-227, 1989
3. Hill G, Krementz ET, Hill HZ: Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma, late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A). Cancer 53:1299-1305, 1984
4. Markowitz JS, Cosimi LA, Care RW, et al: Prognosis after initial recurrence of cutaneous melanoma. Arch Surg 126:703-708, 1991
5. Barth A, Wanek LA, Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 181:193-201, 1995
6. Balch CM, Soong S, Shaw HM, et al: An analysis of prognostic factors in 8500 patients with cutaneous melanoma, in Balch CM, Houghton AN, Milton GW (eds): Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott, 1992, pp 180-186
7. Sirott MN, Bajorin DF, Wong GYC, et al: Prognostic factors in patients with metastatic melanoma: A multivariate analysis. Cancer 72:3091-3098, 1993
8. Ryan L, Kramar A, Borden E: Prognostic factors in metastatic melanoma. Cancer 71:2995-3005, 1993
9. Anderson JR, Crowley JJ, Propert KJ: Interpretation of survival data in clinical trials. Oncology 5:104-114, 1991
10. Polyzos A, Legha SS, Burgess AM, et al: Phase II study of AMSA alone and in combination with DTIC in patients with melanoma. Invest New Drugs 6:57-61, 1988
11. Verschraegen CF, Legha SS, Hersh EM, et al: Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma. Eur J Cancer 29A:708-711, 1993
12. Legha SS, Papadopoulos N, Plager C, et al: Clinical evaluation of recombinant interferon alfa-2A (Roferon-A) in metastatic melanoma using two different schedules. J Clin Oncol 5:1240-1246, 1987
13. Papadopoulos N, Ring S, Plager C, et al: Sequential use of vincristine (V), DTIC (D), and hydroxyurea (H) in advanced malignant melanoma. Proc Am Soc Clin Oncol 6:208, 1987 (abstr 822)
14. Legha SS, Ring S, Papadopoulos N, et al: A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer 64:2024-2029, 1989
15. Beahrs OH, Henson DE, Hutter RVP, et al (eds): Manual for Staging of Cancer (ed 4). Philadelphia, PA, Lippincott, 1992
16. Hermanek P, Sobin LH (eds): UICC TNM Classification of Malignant Tumors (ed 4). Berlin, Germany, Springer-Verlag, 1992
17. Stidham KR, Johnson JL, Seigler HF: Survival superiority of females with melanoma. A multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg 29:316-324, 1994
18. Keilholz U, Scheibenbogen C, Sommer M et al: Prognostic factors for response and survival in patients with metastatic melanoma receiving immunotherapy. Mel Res 6:173-178, 1996
19. Legha SS, Ring S, Bedikian A et al: Treatment of metastatic melanoma treated with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon alfa. Ann Oncol 7:827-835, 1996